Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 for intestinal malabsorption in preterm infants
2024-517101-87-00Phase 3Authorised
- Sponsor
- Elgan Pharma
- Start
- May 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in intestinal malabsorption comparing ELGN-2112 with Placebo (2 arms). Primary endpoint: Time to full enteral feeding. Planned start May 2025; status: authorised.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on 2024-517101-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517101-87-00.